Market Executive Summary

The global market for Cancer Tumor Profiling was estimated to be worth US$ 49140 million in 2024 and is forecast to a readjusted size of US$ 97300 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.

Cancer/tumor profiling provides information about the genes causing cancer, which would offer useful insights related to the mechanism of cancer. The potential of cancer profiling is not only limited to common cancers, such as lymphoma and breast cancer, but also is useful in molecular profiling of lung cancer, prostate cancer, and acute leukemia. Cancer profiling has plays a vital role in diagnosis at the molecular level, as better understanding of the cancer tumors helps physicians to make appropriate therapeutic decisions and avoid “over-treatment” of the cancer patients.

The global market is driven by growing demand for cancer profiling method by oncologists to diagnose or treat cancers as well as predict response to targeted therapy. In addition, rise in adoption of cancer biomarkers for tumor profiling, increase in incidence of cancer across the globe, and growth in use of next-generation sequencing technique for cancer profiling boost the market growth. However, high monetary investments for the development of biomarkers and dearth of skilled professionals or oncologists specific to tumor profiling hamper the market growth.

This report aims to provide a comprehensive presentation of the global market for Cancer Tumor Profiling, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cancer Tumor Profiling by region & country, by Type, and by Application.

The Cancer Tumor Profiling market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Tumor Profiling.

Global Cancer Tumor Profiling Companies Covered

Qiagen N.V.

Roche Molecular Systems Inc.

Abott Molecular

Illumina Inc.

NeoGenomics Laboratories

HTG Molecular Diagnostic

Genomic Health Inc.

Hologic Gen-Probe

BD Biosciences

Siemens Healthineers

Claris Life Sciences

Personal Genome Diagnostics, Inc.

Perthera, Inc.

Foundation Medicine, Inc

V., Strand

ApoCell

Contextual Genomics

Agendia

GenScript

Global Cancer Tumor Profiling Market, by Region

North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Cancer Tumor Profiling Market, Segment by Type

Next-generation Sequencing (NGS)

Polymerase Chain Reaction (PCR)

Immunohistochemistry (IHC)

In Situ Hybridization (ISH)

Microarray

Others

Global Cancer Tumor Profiling Market, Segment by Application

Personalized Medicine

Diagnostics

Biomarker Discovery

Prognostics

Research Applications

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Cancer Tumor Profiling company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Cancer Tumor Profiling in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Cancer Tumor Profiling in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.